PD-1/PD-L1 inhibitors combination therapy for unresectable HCC was associated with better OS, PFS, ORR, and DCR than anti-angiogenic monotherapy, especially for the first-time discovery of better survival benefits for HBV infection and Asian population. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.